Findings from the phase 3 ADAPT SERON trial demonstrated that efgartigimod IV significantly improved MG-ADL total scores in patients who were acetylcholine receptor antibody seronegative. The Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results